Skip to main content
SpringerLink
Log in

Active Surveillance: The European Experience

  • Chapter
  • First Online:
Active Surveillance for Localized Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 681 Accesses

Abstract

PC is the most frequently diagnosed malignancy in men across Europe. After PSA became available as a potential screening tool for the early detection of PC, the incidence of the disease has been increasing, as well as the relative amount of low-risk and potentially overdiagnosed disease. Active surveillance has emerged over the last few years as an alternative treatment strategy for the management of potentially overdiagnosed prostate cancer.

In this chapter, the European studies and initiatives with respect to screening for prostate cancer, and feasibility and effectiveness of active surveillance, are described. There are two ongoing prospective active surveillance studies in Europe; the study at the Royal Marsden Hospital in the United Kingdom was initiated in 2002, and the PRIAS study was initiated in the Netherlands in 2006 and is now an international web-based program with the highest number of participants worldwide.

Current results regarding active surveillance look promising, but longer follow-up is warranted to improve inclusion and follow-up criteria and evaluate the safety of this approach. Furthermore, future research will focus on the improvement of the individualized management of patients with low-risk prostate cancer by means of predictive tools, and the incorporation of new biomarkers and imaging techniques for the differentiation between potentially aggressive and indolent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.

    Article  PubMed  CAS  Google Scholar 

  2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16.

    Article  PubMed  CAS  Google Scholar 

  3. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17): 1156–61.

    Article  PubMed  CAS  Google Scholar 

  4. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040–52.

    Article  PubMed  CAS  Google Scholar 

  5. Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int. 2005;95(2):231–7.

    Article  PubMed  Google Scholar 

  6. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.

    Article  PubMed  Google Scholar 

  7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12): 1250–61.

    Article  PubMed  CAS  Google Scholar 

  8. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol. 2008;179(5 Suppl):S40–4.

    Article  PubMed  Google Scholar 

  9. Fransson P. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer–15 years’ follow-up. A comparison with age-matched controls. Acta Oncol. 2008;47(5): 852–61.

    Article  PubMed  Google Scholar 

  10. Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85.

    Article  PubMed  Google Scholar 

  11. Karakiewicz PI, Benayoun S, Kattan MW, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005;173(6):1930–4.

    Article  PubMed  Google Scholar 

  12. Perdona S, Cavadas V, Di Lorenzo G, et al. Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol. 2011;59:81–7.

    Article  PubMed  Google Scholar 

  13. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24(1):46–50.

    Article  PubMed  Google Scholar 

  14. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5(2):101–6.

    Article  PubMed  Google Scholar 

  15. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51(5):1244–50. discussion 1251.

    Article  PubMed  Google Scholar 

  16. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–78.

    Article  PubMed  Google Scholar 

  17. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.

    Article  PubMed  Google Scholar 

  18. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010; 126(10):2387–93.

    PubMed  CAS  Google Scholar 

  19. Roobol MJ, Kerkhof M, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009;56(4):584–91.

    Article  PubMed  Google Scholar 

  20. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–32.

    Article  PubMed  Google Scholar 

  21. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010;46(17):3095–101.

    Article  PubMed  CAS  Google Scholar 

  22. Donovan J, Hamdy F, Neal D, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1–88.

    PubMed  CAS  Google Scholar 

  23. Bartsch G, Horninger W, Klocker H, et al. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008;101(7):809–16.

    Article  PubMed  CAS  Google Scholar 

  24. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer. 2007;120(1):170–4.

    Article  PubMed  Google Scholar 

  25. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008; 100(16):1144–54.

    Article  PubMed  Google Scholar 

  26. Schulz RJ, Kagan AR. Re: prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst. 2009;101(2):124.

    Article  PubMed  Google Scholar 

  27. Albertsen PC. A challenge to contemporary management of prostate cancer. Nat Clin Pract Urol. 2009; 6(1):12–3.

    Article  PubMed  Google Scholar 

  28. Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102(13):950–8.

    Article  PubMed  Google Scholar 

  29. Khatami A, Damber JE, Lodding P, Pihl CG, Hugosson J. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?–a case control study. Scand J Urol Nephrol. 2003;37(3):213–7.

    Article  PubMed  Google Scholar 

  30. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55(1):1–8.

    Article  PubMed  Google Scholar 

  31. van den Bergh RC, Steyerberg EW, Khatami A, et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer. 2010; 116(5):1281–90.

    Article  PubMed  Google Scholar 

  32. van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J. 2007;13(5):289–94.

    Article  PubMed  Google Scholar 

  33. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54(6):1297–305.

    Article  PubMed  Google Scholar 

  34. Ng MK, Van As N, Thomas K, et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int. 2009;103(7):872–6.

    Article  PubMed  CAS  Google Scholar 

  35. Prostate Cancer Research International: Active Surveillance. www.prias-project.org. Accessed 1 Jan 2011.

  36. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007;52(6):1560–3.

    Article  PubMed  Google Scholar 

  37. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int. 2010;105(7):956–62.

    Article  PubMed  Google Scholar 

  38. van den Bergh RC, van Vugt HA, Korfage IJ, et al. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int. 2010;105(3):322–8.

    Article  PubMed  Google Scholar 

  39. van den Bergh RC, Essink-Bot ML, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115(17):3868–78.

    Article  PubMed  Google Scholar 

  40. van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol. 2010; 183(5):1786–91.

    Article  PubMed  Google Scholar 

  41. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003;170(5): 1792–7.

    Article  PubMed  Google Scholar 

  42. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007;177(1):107–12.

    Article  PubMed  CAS  Google Scholar 

  43. Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol. 2008;180(1):150–4. discussion 154.

    Article  PubMed  Google Scholar 

  44. Schnell D, Schon H, Weissbach L. [Therapy of local prostate carcinoma. Questions answered by outcome research] Therapie des lokal begrenzten Prostatakarzinoms Fragen beantwortet die Versorgungsforschung. Urologe Ausgabe A. 2009;48(9):1050–5.

    Article  CAS  Google Scholar 

  45. Futterer JJ, Barentsz J, Heijmijnk ST. Imaging modalities for prostate cancer. Expert Rev Anticancer Ther. 2009;9(7):923–37.

    Article  PubMed  Google Scholar 

  46. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59:962–77.

    Article  PubMed  Google Scholar 

  47. Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol. 2011;84(997): 31–7.

    Article  PubMed  CAS  Google Scholar 

  48. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol. 2009;56(6):981–7.

    Article  PubMed  Google Scholar 

  49. Ploussard G, Xylinas E, Durand X, et al. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. BJU Int. 2011;108:513–7.

    Article  PubMed  Google Scholar 

  50. Braeckman J, Autier P, Garbar C, et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008;101(3):293–8.

    Article  PubMed  Google Scholar 

  51. Braeckman J, Autier P, Soviany C, et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008;102(11):1560–5.

    Article  PubMed  Google Scholar 

  52. Roobol MJ, Schroder FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010;58(4):475–81.

    Article  PubMed  CAS  Google Scholar 

  53. Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011;59:422–9.

    Article  PubMed  Google Scholar 

  54. Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int. 2010;106(2):280–6.

    Article  PubMed  Google Scholar 

  55. Thomasson M, Wang B, Hammarsten P, et al. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer. 2011;128:2843–52.

    Article  Google Scholar 

  56. Jhavar S, Bartlett J, Kovacs G, et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis. 2009; 12(2):143–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, Erasmus University Medical Centre, 2040, Rotterdam, The Netherlands

    Meelan Bul M.D., Monique J. Roobol Ph.D. & Chris H. Bangma M.D., Ph.D.

Authors
  1. Meelan Bul M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monique J. Roobol Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris H. Bangma M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Toronto, Sunnybrook Health Sciences Centre, Division of Urology, Toronto, M4N 3M5, Ontario, Canada

    Laurence Klotz

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bul, M., Roobol, M.J., Bangma, C.H. (2012). Active Surveillance: The European Experience. In: Klotz, L. (eds) Active Surveillance for Localized Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-912-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-912-9_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-911-2

  • Online ISBN: 978-1-61779-912-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation